Evidence map›Paper›PMID 33406631›Full record

ArticleJournal of personalized medicine2021

Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter?

Valentyn Fournier, Thomas Prebet, Alexandra Dormal, Maïté Brunel, Robin Cremer, Loris Schiaratura

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. In Silico Clinical Trials: Is It Possible?Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Valentyn FournierUniversity of Lille, ULR 4072-PSITEC-Psychologie: Interactions, Temps, Emotions, Cognition, F-59000 Lille, France.ORCID 0000-0002-1289-8968
Thomas PrebetYale Cancer Center, Yale University, 333 Cedar Street, New Haven, CT 06520, USA.
Alexandra DormalYale Cancer Center, Yale University, 333 Cedar Street, New Haven, CT 06520, USA.
Maïté BrunelUniversity of Lille, ULR 4072-PSITEC-Psychologie: Interactions, Temps, Emotions, Cognition, F-59000 Lille, France.
Robin CremerEspace éthique régional des Hauts-de-France, Centre Hospitalier Universitaire de Lille, F-59037 Lille, France.
Loris SchiaraturaUniversity of Lille, ULR 4072-PSITEC-Psychologie: Interactions, Temps, Emotions, Cognition, F-59000 Lille, France.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Institut National Du Cancer DOC2018NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Personalized medicine (PM) is increasingly becoming a topic of discussion in public health policies and media. However, there is no consensus among definitions of PM in the scientific literature and the terms used to designate it, with some definitions emphasizing patient-centered aspects and others emphasizing biomedical aspects. Furthermore, terms used to refer to PM (e.g., "pharmacogenomics" or, more often, "targeted therapies") are diverse and differently used. To our knowledge, no study has apprehended the differences of definition and attitudes toward personalized medicine and targeted therapies according to level of familiarity with the medical field. Our cohort included 349 French students from three different academic fields, which modulated their familiarity level with the medical field. They were asked to associate words either to "personalized medicine" or "target therapies". Then, they were asked to give an emotional valence to their associations. Results showed that nonfamiliar students perceived PM as more positive than targeted therapies (TT), whereas familiar students showed no difference. Only familiar students defined PM and TT with technical aspects such as genetics or immunology. Further studies are needed in the field in order to determine which other factors could influence the definitions of PM and TT and determine how these definitions could have an impact in a clinical setting.

Indexed as

attitudesdefinitionfamiliaritygeneticsgenomicspersonalized medicinetargeted therapies

Identifiers

PMID33406631
PMCPMC7824594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.